JPRN-UMIN000042975已完成未知
A multi-institutional retrospective study of dacomitinib in rechallenge setting for patients with EGFR mutation (TOPGAN2020-02) - TOPGAN2020-02
TOPGAN group0 个研究点目标入组 40 人开始时间: 2021年1月15日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
The median progression-free survival (PFS) was 4.3 months (95% confidence interval [CI], 2.5-5.6). The overall survival (OS) was 10.5 months (95% CI, 7.4-not reached).
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
2 期
Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaHead and Neck NeoplasmsNeoplasm Recurrence, LocalNeoplasm MetastasisNCT00401323Sanofi568
进行中（未招募）
3 期
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)NCT06211764Janssen Research & Development, LLC272
已完成
不适用
Practice in the Radiation Therapy for Stage D1 Prostate Cancer: Survey of the Japanese Radiation Oncology Study Group (JROSG)Radiation therapy for stage D1 prostate cancerJPRN-UMIN000035990ihon University school of medicine169
终止
3 期
Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer PatientsProstate CancerNCT00133224Cell Genesys408
已完成
3 期
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck CancersCarcinoma, Squamous Cell of the Head and NeckNCT01166542Oncolytics Biotech167